Recro Pharma Inc. buy tamam
Start price
22.03.17
/
50%
€6.89
Target price
04.11.21
€19.00
Performance (%)
-76.20%
End price
05.11.21
€1.64
Summary
This prediction ended on 05.11.21 with a price of €1.64. Massive losses of -76.20% were the result for the BUY prediction by tamam. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Recro Pharma Inc. | - | - | - | - |
| iShares Core DAX® | 0.961% | -2.210% | 12.839% | 17.154% |
| iShares Nasdaq 100 | 2.626% | -1.918% | 38.498% | 45.463% |
| iShares Nikkei 225® | 0.217% | -7.216% | 19.425% | 5.076% |
| iShares S&P 500 | 1.540% | -1.858% | 27.801% | 42.583% |
Comments by tamam for this prediction
In the thread Recro Pharma Inc. diskutieren
Recro Pharma announced positive results from its second phase 3 -
-clinical trial evaluating intravenous (IV) meloxicam for the treatment
of acute post-operative pain following abdominoplasty surgery.
The company has three primary drug candidates in development, the most important is an IV version of Meloxicam which is in late stage testing for acute post-operative pain.
The company filed a New Drug Application for IV Meloxicam in late July.
This means the FDA should accept the application in the coming days and
make a decision on approval late in the first half of 2018.
Upcoming catalysts in 2017 could boost sentiment on the stock and increasing positive commentary on the concern from analysts could trigger this as well.
Kursziel geändert auf 19,0
In the thread Trading Recro Pharma Inc.
Die von tamam gewählte maximale Laufzeit wurde überschritten